Mabwell’s experimental therapy 9MW1911 may reduce the frequency of moderate to severe exacerbations in people with chronic obstructive pulmonary disease (COPD), according to data from a completed Phase 2a clinical trial. The results were announced in a press release from Mabwell. The company is now conducting a…